Lancet Rheumatology: 硬皮病患者为中心的干预网络 (SPIN) 队列中的疼痛水平和相关因素:一项多中心横断面研究

2021-12-13 MedSci原创 MedSci原创

疼痛在系统性硬化症患者中很常见。控制社会人口学变量后,更大的疼痛与多种系统性硬化症相关的症状有关,包括关节挛缩、手指溃疡、胃肠道受累、皮肤受累和重叠综合征的存在。

      疼痛是系统性硬化症(又称为硬皮病)的一个重要且有害的特征,但在研究和临床护理中经常被忽视或不优先考虑。雷诺现象、关节炎和皮肤溃疡是系统性硬化症的常见疾病表现,可能与疼痛有关。该研究旨在评估疼痛强度和干扰的水平,并评估与它们相关的疾病因素。

       在这项多中心横断面研究中,来自硬皮病患者为中心的干预网络队列的参与者包括完成疼痛强度和干预措施作为基线评估的一部分。患者是在2014415日至202017日期间从澳大利亚、加拿大、法国、墨西哥、西班牙、英国和美国的46个中心招募的。纳入标准是满足美国风湿病学会和欧洲抗风湿病联盟标准的成人硬化症。通过多元线性回归评估疼痛强度和疼痛干扰与系统性硬化症相关变量和重叠综合征的关联,校正社会人口学变量,标准化连续自变量

      在2157名患有系统性硬化症的参与者(268 [12%]男性和1889[88%]女性)中,1870(87%)报告有轻度、中度或重度疼痛(定义为010的等级≥1),以及815 (38%) 报告有中度或重度疼痛(定义为≥5)。此外,757 (35%) 名参与者报告了中度或重度疼痛干扰。较大的疼痛强度与女性(0.58 [95% CI 0.260.90])、非白人种族(0.50 [0.21-0.79])独立相关,更少的正规教育(每个SD [0.19-0.41] 0.30 分)、国家(以美国为参考;加拿大:0.29[0.01-0.57] 和英国:0.58[0.210.95]),更大的体重指数(每个SD 0.35 [0.24-0.45]);关节挛缩(0.67[0.39-0.94]),手指溃疡(0.33[0.10-0.55]),胃肠道受累(0.66[0.33-0.55])、皮肤受累(使用改良的Rodnan皮肤评分测量;每个SD 0.22[0.10-0.35])、类风湿性关节炎0.96[0.50-1.43]),以及干燥综合征(0.42[0.010.83])。疼痛干扰结果相似。

      疼痛在系统性硬化症患者中很常见。控制社会人口学变量后,更大的疼痛与多种系统性硬化症相关的症状有关,包括关节挛缩、手指溃疡、胃肠道受累、皮肤受累和重叠综合征的存在。医生应与患者合作解决疼痛问题,包括识别和解决与其疼痛相关的系统性硬化症表现,并支持行为治疗以尽量减少对功能和生活质量的影响。

 

出处:

Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional studyLee, Yvonne CHenry, Richard S. et al.The Lancet Rheumatology, Volume 3, Issue 12, e844 - e854

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2041585, encodeId=46c1204158565, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 25 08:33:42 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904098, encodeId=2f621904098b7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jan 11 20:33:42 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062568, encodeId=ba1f20625685c, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 19 23:33:42 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 20:33:42 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377141, encodeId=448813e714192, content=<a href='/topic/show?id=dccfe3605ff' target=_blank style='color:#2F92EE;'>#硬皮病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73605, encryptionId=dccfe3605ff, topicName=硬皮病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457550, encodeId=641e145e55021, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079477, encodeId=eb4b10e9477f9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c5d6392836, createdName=ms8000001062231879, createdTime=Mon Dec 13 10:43:30 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2041585, encodeId=46c1204158565, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 25 08:33:42 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904098, encodeId=2f621904098b7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jan 11 20:33:42 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062568, encodeId=ba1f20625685c, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 19 23:33:42 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 20:33:42 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377141, encodeId=448813e714192, content=<a href='/topic/show?id=dccfe3605ff' target=_blank style='color:#2F92EE;'>#硬皮病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73605, encryptionId=dccfe3605ff, topicName=硬皮病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457550, encodeId=641e145e55021, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079477, encodeId=eb4b10e9477f9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c5d6392836, createdName=ms8000001062231879, createdTime=Mon Dec 13 10:43:30 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2041585, encodeId=46c1204158565, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 25 08:33:42 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904098, encodeId=2f621904098b7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jan 11 20:33:42 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062568, encodeId=ba1f20625685c, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 19 23:33:42 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 20:33:42 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377141, encodeId=448813e714192, content=<a href='/topic/show?id=dccfe3605ff' target=_blank style='color:#2F92EE;'>#硬皮病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73605, encryptionId=dccfe3605ff, topicName=硬皮病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457550, encodeId=641e145e55021, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079477, encodeId=eb4b10e9477f9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c5d6392836, createdName=ms8000001062231879, createdTime=Mon Dec 13 10:43:30 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2041585, encodeId=46c1204158565, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 25 08:33:42 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904098, encodeId=2f621904098b7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jan 11 20:33:42 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062568, encodeId=ba1f20625685c, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 19 23:33:42 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 20:33:42 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377141, encodeId=448813e714192, content=<a href='/topic/show?id=dccfe3605ff' target=_blank style='color:#2F92EE;'>#硬皮病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73605, encryptionId=dccfe3605ff, topicName=硬皮病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457550, encodeId=641e145e55021, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079477, encodeId=eb4b10e9477f9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c5d6392836, createdName=ms8000001062231879, createdTime=Mon Dec 13 10:43:30 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2022-07-19 howi
  5. [GetPortalCommentsPageByObjectIdResponse(id=2041585, encodeId=46c1204158565, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 25 08:33:42 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904098, encodeId=2f621904098b7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jan 11 20:33:42 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062568, encodeId=ba1f20625685c, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 19 23:33:42 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 20:33:42 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377141, encodeId=448813e714192, content=<a href='/topic/show?id=dccfe3605ff' target=_blank style='color:#2F92EE;'>#硬皮病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73605, encryptionId=dccfe3605ff, topicName=硬皮病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457550, encodeId=641e145e55021, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079477, encodeId=eb4b10e9477f9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c5d6392836, createdName=ms8000001062231879, createdTime=Mon Dec 13 10:43:30 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-15 rgjl
  6. [GetPortalCommentsPageByObjectIdResponse(id=2041585, encodeId=46c1204158565, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 25 08:33:42 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904098, encodeId=2f621904098b7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jan 11 20:33:42 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062568, encodeId=ba1f20625685c, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 19 23:33:42 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 20:33:42 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377141, encodeId=448813e714192, content=<a href='/topic/show?id=dccfe3605ff' target=_blank style='color:#2F92EE;'>#硬皮病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73605, encryptionId=dccfe3605ff, topicName=硬皮病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457550, encodeId=641e145e55021, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079477, encodeId=eb4b10e9477f9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c5d6392836, createdName=ms8000001062231879, createdTime=Mon Dec 13 10:43:30 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2041585, encodeId=46c1204158565, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 25 08:33:42 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904098, encodeId=2f621904098b7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jan 11 20:33:42 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062568, encodeId=ba1f20625685c, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 19 23:33:42 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 19 20:33:42 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377141, encodeId=448813e714192, content=<a href='/topic/show?id=dccfe3605ff' target=_blank style='color:#2F92EE;'>#硬皮病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73605, encryptionId=dccfe3605ff, topicName=硬皮病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457550, encodeId=641e145e55021, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Wed Dec 15 01:33:42 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079477, encodeId=eb4b10e9477f9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c5d6392836, createdName=ms8000001062231879, createdTime=Mon Dec 13 10:43:30 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-13 ms8000001062231879

    学习了

    0

相关资讯

万万没想到,“神药”二甲双胍会在这“小病”遇滑铁卢?

DARU Journal of Pharmaceutical Sciences:二甲双胍治疗纤维囊性乳腺病:一项安慰剂对照随机临床试验

BMJ Open:水凝胶敷料作为急救手段辅助治疗小儿急性烧伤的有效性:一项前瞻性的随机对照试验

近日,发表于BMJ Open的一项单中心、优越性、双臂、平行组、前瞻性随机对照试验比较了两种急性烧伤敷料在降低小儿烧伤患者适当急救后的急性疼痛评分方面的效

Journal of Physiotherapy :患者教育可改善膝骨关节炎患者的疼痛和功能,与运动疗法结合使用效果更佳 !

膝关节骨关节炎(OA)是世界范围内致残的主要原因,50岁以上的人中有四分之一受到影响。在许多发达国家,与膝关节骨关节炎相关的日益增长的医疗负担被认为是不可持续的。例如,2013年澳大利亚仅在膝关节置换

疼痛的新定义及慢性疼痛的分类

2020年7月16日,国际疼痛学会对"疼痛" 定义进行了修改,并在线发表在其会刊《PAIN》杂志上。这是IASP对自1979年开始在全世界使用的疼痛定义的首次修订。